Joseph Baker

Nov 17, 2024 | onlinelibrary.wiley.com | Joseph Baker |Andrew Whitehead

REFERENCES . (2018). Piercing the blue wall with the Gospel. Decision Magazine. Accessed August 23, 2024. Available at: https://decisionmagazine.com/piercing-the-blue-wall-with-the-gospel/ , , , , & (2021). Protecting America's borders: Christian nationalism, threat, and attitudes toward immigrants in the United States. Group Processes & Intergroup Relations, 25(2), 354–378. https://doi.org/10.1177/1368430220978291 , , , & (2022).

Feb 26, 2024 | mlo-online.com | Christina Wichmann |Joseph Baker

Quest Diagnostics Health Trends topics are selected with expectations that reports may reveal important new novel public health insights. We collaborate with national academic experts and leaders in public health on many of our studies. To find impactful findings, this external input helps shape the objectives and study designs. Many of our studies have been highlighted by premier news outlets, nationally and regionally, and have been integrated into professional guidelines.

Feb 7, 2024 | mlo-online.com | Christina Wichmann |Joseph Baker

Helio Genomics has announced that Gary Frazier has been selected as Chief Growth Officer for the firm. Frazier brings extensive experience in several key aspects of healthcare to the position. Frazier is the founder and CEO of two healthcare entities. Worksite Labs is an innovative diagnostic laboratory company. OM Healthcare is a digital front door software for direct-to-consumer healthcare. His experience also includes executive positions in several aspects of healthcare systems management.

Feb 1, 2024 | mlo-online.com | Joseph Baker

The Administration announced that sickle cell disease (SCD) will be the first focus of the Cell and Gene Therapy (CGT) Access Model, which was initially announced in February 2023. The model is designed to improve health outcomes, increase access to cell and gene therapies, and lower healthcare costs for some of the nation’s most vulnerable populations.

Jan 29, 2024 | mlo-online.com | Christina Wichmann |Joseph Baker

First, AMP prefers to use the term laboratory developed testing procedures (LDPs) instead of LDTs since these tests are essential clinical services. LDPs are vital laboratory services that are designed, developed, validated, performed, and interpreted by board-certified professionals in regulated clinical laboratories. They are being used across a range of applications including oncology, rare disease diagnosis, newborn screening, infectious disease testing, and more.